Value-based decision-making for orphan drugs with multiple criteria decision analysis: burosumab for the treatment of X-linked hypophosphatemia-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Value-based decision-making for orphan drugs with multiple criteria decision analysis: burosumab for the treatment of X-linked hypophosphatemia

Published:2021-04-01 Issue:6 Volume:37 Page:1021-1030
ISSN:0300-7995
Container-title:Current Medical Research and Opinion
language:en
Short-container-title:Current Medical Research and Opinion

Author:

Vandewalle Björn¹,Amorim Miguel¹,Ramos Diogo¹,Azevedo Sofia¹,Alves Inês²,Francisco Telma³,Pinto Helena⁴,Sousa Sérgio⁵

Affiliation:

1. Exigo Consultores, Lisbon, Portugal

2. Associação Nacional de Displasias Ósseas, Évora, Portugal

3. Centro Hospitalar Universitário Lisboa Central, Lisbon, Portugal

4. Centro Hospitalar Universitário de São João, Porto, Portugal

5. Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal

Publisher

Informa UK Limited

Subject

General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/03007995.2021.1904861

Reference38 articles.

1. X-linked hypophosphatemia and growth

2. Hypophosphatemic rickets: etiology, clinical features and treatment

3. A clinician's guide to X-linked hypophosphatemia

4. Ruppe MD. X-linked hypophosphatemia, Gene Reviews. Seattle (WA): University of Washington; 2017.

5. X-linked hypophosphatemic rickets: A study (with literature review) of linear growth response to calcitriol and phosphate therapy

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Scoping review of economic analyses of rare kidney diseases;Kidney International Reports;2024-09

2. X-linked hypophosphataemia;The Lancet;2024-08

3. Bone Matrix Mineralization and Response to Burosumab in Adult Patients With X‐Linked Hypophosphatemia: Results From the Phase 3, Single‐Arm International Trial;Journal of Bone and Mineral Research;2022-08-10

4. Health-related quality of life of X-linked hypophosphatemia in Spain;Orphanet Journal of Rare Diseases;2022-07-29

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3